Oryzon Genomics Logo

Oryzon Genomics Logo (full size)

Oryzon Genomics Logo icon/symbol

Oryzon Genomics Logo (full size) on a dark background

Oryzon Genomics Logo icon/symbol on a dark background

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellร  de Llobregat, Spain.

Page last updated on:

calendar iconOctober 3rd, 2024

Categories: